nisoldipine has been researched along with Epilepsy in 2 studies
Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.
nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.
methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twelve patients with epilepsy receiving chronic phenytoin therapy and 12 healthy control subjects matched for age and gender received a single oral dose of nisoldipine (40 and 20 mg, respectively)." | 7.69 | Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy. ( Cipolla, G; Gatti, G; Heinig, R; Michelucci, R; Ochan, M; Passarelli, D; Perucca, E; Tassinari, CA, 1996) |
| "Twelve patients with epilepsy receiving chronic phenytoin therapy and 12 healthy control subjects matched for age and gender received a single oral dose of nisoldipine (40 and 20 mg, respectively)." | 3.69 | Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy. ( Cipolla, G; Gatti, G; Heinig, R; Michelucci, R; Ochan, M; Passarelli, D; Perucca, E; Tassinari, CA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doyle, KM | 1 |
| Kirby, BP | 1 |
| Murphy, D | 1 |
| Shaw, GG | 1 |
| Michelucci, R | 1 |
| Cipolla, G | 1 |
| Passarelli, D | 1 |
| Gatti, G | 1 |
| Ochan, M | 1 |
| Heinig, R | 1 |
| Tassinari, CA | 1 |
| Perucca, E | 1 |
2 other studies available for nisoldipine and Epilepsy
| Article | Year |
|---|---|
Effect of L-type calcium channel antagonists on spermine-induced CNS excitation in vivo.
Topics: Amines; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Central Nervous System; Convuls | 2005 |
Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy.
Topics: Adult; Contraindications; Delayed-Action Preparations; Drug Interactions; Epilepsy; Female; Humans; | 1996 |